Septerna Inc. (SEPN)
Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease.
It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes.
Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.
The company was incorporated in 2019 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Oct 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Dr. Jeffrey T. Finer M.D., Ph.D. |
Contact Details
Address: 250 East Grand Avenue South San Francisco, California United States | |
| Website | https://septerna.com |
Stock Details
| Ticker Symbol | SEPN |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001984086 |
| CUSIP Number | 81734D104 |
| ISIN Number | US81734D1046 |
| Employer ID | 84-3891440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Elizabeth P. Bhatt M.B.A., M.S. | Chief Operating Officer |
| Gilbert M. Labrucherie C.F.A., J.D. | Chief Financial Officer |
| Samira Shaikhly | Chief People Officer |
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Dr. Jae B. Kim FACC, M.D. | Chief Medical Officer |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| George Xu Ph.D. | Senior Director of Corporate Development & Portfolio Strategy |
| Richard Hansen Ph.D. | Vice President of Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 14, 2025 | 8-K | Current Report |
| May 09, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 04, 2025 | 4 | Filing |